Biotransformation Changes Bioaccumulation and Toxicity of Diclofenac in Aquatic Organisms

Qiuguo Fu¹ *, Davide Fedrizzi¹, Verena Kosfeld²,³, Christian Schlechtriem²,³, Vera Ganz¹,⁴, Samuel Derrer¹, Daniel Rentsch⁵, Juliane Hollender¹,⁴, *

¹Eawag, Swiss Federal Institute of Aquatic Science and Technology, 8600 Dübendorf, Switzerland
²Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Schmallenberg, Germany
³Institute for Environmental Research (Biology V), 52074 Aachen, Germany
⁴Institute of Biogeochemistry and Pollutant Dynamics, ETH Zürich, 8092 Zürich, Switzerland
⁵EMPA, Swiss Federal Laboratories for Materials Science and Technology, 8600 Dübendorf, Switzerland

*Correspondence to:
Prof. Dr. Juliane Hollender and Dr. Qiuguo Fu
Environmental Chemistry,
Eawag, Swiss Federal Institute of Aquatic Science and Technology
(www.eawag.ch)
Überlandstrasse 133, 8600 Dübendorf, Switzerland
E-Mail: juliane.hollender@eawag.ch; qiuguo.fu@eawag.ch
Phone: +41 58 765 5493
Fax: +41 58 765 5893

Word count (6706 equivalent): main text (5806) + 3 figures (900)

This document is the accepted manuscript version of the following article:

https://doi.org/10.1021/acs.est.9b07127
**Abstract:**

Biotransformation plays a crucial role in regulating the bioaccumulation potential and toxicity of organic compounds in organisms but is, in general, poorly understood for emerging contaminants. Here we have used diclofenac as a model compound to study the impact of biotransformation on the bioaccumulation potential and toxicity in two keystone aquatic invertebrates: *Gammarus pulex* and *Hyalella azteca*. In both species, diclofenac was transformed into several oxidation products and conjugates, including two novel products, i.e. diclofenac taurine conjugate (DCF-M403) and unexpected diclofenac methyl ester (DCF-M310.03). The ratios of biotransformation products to parent compound were 12-17 for DCF-M403 and 0.01-0.7 for DCF-M310.03 after 24 h exposure. Bioconcentration factors (BCFs) of diclofenac were 0.5 and 3.2 L kg\(^{-1}\)\(\text{ww}\) in *H. azteca* and *G. pulex*, respectively, whereas BCFs of DCF-M310.03 was 164.5 L kg\(^{-1}\)\(\text{ww}\) and 104.7 L kg\(^{-1}\)\(\text{ww}\), respectively, representing a 25 to 110-fold increase. Acute toxicity of DCF-M310.03 was also higher than the parent compound in both species, which correlated well with the increased bioconcentration potential. The LC\(_{50}\) of diclofenac in *H. azteca* was 216 mg L\(^{-1}\), while that of metabolite DCF-M310.03 was reduced to only 0.53 mg L\(^{-1}\), representing a 430-fold increase in acute toxicity compared to diclofenac. DCF-M403 is less toxic than its parent compound towards *H. azteca*, which may be linked to its slightly lower hydrophobicity. Furthermore, the transformation of diclofenac to its methyl ester derivative was explored in crude invertebrate extracts spiked with an S-adenosylmethionine cofactor, revealing possible catalysis by an S-adenosylmethionine-dependent -carboxylic acid methyltransferase. Methylation of diclofenac was further detected in fish hepatocytes and human urine, indicating a broader relevance. Therefore, potentially methylated metabolites of polar contaminants should be considered for a comprehensive risk assessment in the future.
Keywords: Methylation, Biotransformation, Diclofenac, Acute toxicity, Metabolites, LC-HRMS/MS

Introduction

In the environment, the influence of anthropogenic activities is clearly evidenced by the pervasive occurrence of man-made chemicals as emerging contaminants, such as pharmaceuticals, which have the potential to jeopardize ecosystems and human health.\textsuperscript{1-3} As the global population increases, economies grow as well as health care provision and insurance mechanisms expand, pharmaceutical products are being increasingly used in both human and animal applications.\textsuperscript{4,5} The ubiquitous use of pharmaceuticals in a wide range of settings has resulted in continuous emission of these compounds and their metabolites into the environment, leading to their “pseudo persistence”.\textsuperscript{6} Pharmaceuticals are designed to be biologically active and thus, when taken up, have the potential to exert acute or chronic effects on non-target aquatic organisms, including vertebrate and invertebrate species. For example, the pharmaceutical diclofenac is a heavily used nonsteroidal anti-inflammatory drug in both humans and livestock, with a global annual consumption of up to 1000 tons.\textsuperscript{7} Diclofenac is frequently detected in treated wastewaters, streams, rivers, lakes and even drinking water,\textsuperscript{8-10} with concentration in freshwater reported as high as the µg/L range.\textsuperscript{11,12} Given that at 1 µg L\textsuperscript{-1} diclofenac causes cytological alterations in liver, kidney, and gills of rainbow trout (\textit{Oncorhynchus mykiss})\textsuperscript{13} and, at 5 µg L\textsuperscript{-1}, causes renal lesions and alterations of the gills, it’s possible that environmentally-determined concentrations of diclofenac may pose a risk to aquatic organisms.\textsuperscript{14} Several more studies have revealed toxic effects towards different aquatic species such as common carp (\textit{Cyprinus carpio}),\textsuperscript{15} brown trout (\textit{Salmo trutta fario}),\textsuperscript{16,17} rainbow trout (\textit{Oncorhynchus mykiss})\textsuperscript{13,14,18} and stickleback (\textit{Gasterosteus aculeatus})\textsuperscript{19} at low µg L\textsuperscript{-1} concentrations. In a well-
known incident in Pakistan and India, vulture populations were driven to near extinction after feeding on cattle carcasses containing diclofenac and its residues.\textsuperscript{20,21} As a precaution, diclofenac was added to the watch list under the European Union Water Framework Directive.\textsuperscript{22}

Generally, biotransformation plays a crucial role in regulating the toxicity of chemicals. However, knowledge of relevant metabolites and their formation mechanisms is limited.\textsuperscript{23,24} Risk assessment for these bioactive pharmaceuticals typically operates under the assumption that biotransformation would result in greatly decreased toxicological risks. However, there is growing evidence indicating that metabolites of contaminants such as trenbolone, tetrabromobisphenol-A, bisphenol A, and triclosan maintain the bioactive moieties, are more hydrophobic and, exhibit similar or even greater toxicity.\textsuperscript{25–29} Biotransformation via methylation could lead to more hydrophobic and thus more bioaccumulative metabolites in biological systems and has been detected in fungi, bacteria and plants for different compounds.\textsuperscript{30–32} At present, the biotransformation and non-target toxicity of diclofenac in aquatic organisms, especially invertebrates, is largely unexplored.

In this study, we used diclofenac as a model emerging contaminant to characterize the crucial role of biotransformation in modifying the bioaccumulation potential and toxicity of such compounds, in aquatic organisms. First, we demonstrated the biotransformation patterns of diclofenac in two keystone invertebrate species of the aquatic food web, \textit{Hyalella azteca} and \textit{Gammarus pulex}. Second, we compared the bioaccumulation potential and acute toxicity of the parent compound, diclofenac, and its two main metabolites in these two invertebrates. Third, to determine the broader impact of biotransformation, we investigated whether methylation of diclofenac would occur in other model biological systems, such as fish hepatocytes or humans.
Additionally, we screened methylation of other emerging contaminants with carboxylic and phenolic groups in the tested invertebrates.

**Materials and Methods**

**Chemicals, Solutions, and Test Organisms**

Chemicals and solutions used in this study are provided in the Supporting Information and are listed in Tables S1 and S2. Diclofenac taurine standard was synthesized in house based on a United States patent and identified by NMR spectroscopy. The synthesis protocol and the NMR data of diclofenac taurine are provided in SI. E. Table S6 and Fig. S1-3. *H. azteca* were cultured in aerated Borgmann water (BW) in the lab (23 ± 2 °C, 16 h/8 h light/dark cycle), whereas *G. pulex* were collected from uncontaminated creeks in Switzerland (Location: E 702150, N 2360850) and acclimatized for 3−5 days to the optimal culturing conditions (11 ± 2 °C, 12 h light/12 h dark cycle) in an aquarium with aerated artificial pond water (APW). Details on experiments concerning *H. azteca* and *G. pulex* are provided in SI. B. Rainbow trout hepatocytes (RT-HEPs) were prepared in-house according to a method published by Bischof et al.^[34]^

**Metabolites Screening Experiments In Vivo**

*G. pulex* (number of organisms n=4 per replicate, two replicates) and *H. azteca* (n=30 per replicate, two replicates) were introduced into 600 mL glass beakers filled with 500 mL APW and BW, respectively. *G. pulex* and *H. azteca* were exposed to each chemical for 24 h. An aliquot of 50 μL or 100 μL of stock solution of diclofenac in ethanol (e.g., 10.0 g L⁻¹, and 1.0 g L⁻¹) was spiked to the media to yield an initial chemical concentration of 1 mg L⁻¹(≈ 3.4 μM) and 0.2 mg L⁻¹(≈ 0.68 μM), respectively. The final media contained less than 0.02% organic solvent. Chestnut leaves collected in the creek (or a piece of cotton gauze (6 × 8 cm)) were added
into each beaker and stayed at the bottom of the beaker for *G. pulex* (or *H. azteca*) to perch and hide, respectively. Chestnut leaves also served as a food source for *G. pulex*, whereas *H. azteca* was fed with fish food (ground TetraMin powder). The metabolite screening was performed separately for each selected compound. Experiments were performed in a climate cabinet (Binder KB 115) maintaining the optimal conditions for *G. pulex* (11 ± 2 °C and a 12 h/12 h light/dark cycle) and *H. azteca* (23 ± 2 °C and a 16 h/8 h light/dark cycle). After 24 h exposure, animals were collected, sieved (0.6-mm sieve), quickly rinsed with ultrapure water (18.2 megaohm cm⁻¹), blotted dry using tissue paper, transferred into the pre-weighed 2 mL centrifuge tubes, and weighed. The exposure medium was sampled at the beginning (t₀) and after 24 h (t₂₄) of the experiment. Different controls were performed in parallel, i.e., chemical control (without target compounds, with organisms, leaf or cotton or fish food), organism control (without organisms, with chemical, leaf or cotton) and sorption control (only chemical in pure APW or BW medium, without organisms, leaf, or cotton) and standard control (stock solution of diclofenac in methanol, ethanol or acetonitrile). To investigate the formation of metabolites through abiotic processes during chemical spiking or sample preparation, diclofenac in ethanol was spiked into the vials containing organisms and then the organisms were homogenized and extracted using methanol and acetonitrile separately.

To determine the broader impact of biotransformation, we investigated the biotransformation of diclofenac in humans. Three adult healthy volunteers (two females and one male) provided their informed consent for this study. The age of volunteers was 29, 32, and 54 years old, respectively. Human urine (~10 mL) was collected into the glass vials at 1, 2, 4, and 7 or 8 h after oral administration of a diclofenac tablet (100 mg, 1.3 to 2 mg kg⁻¹ (bodyweight)).
Urine samples were stored at 4 °C in the fridge and analyzed by using LC-HRMS/MS on the same day.

**Metabolites Screening Experiments *In Vitro***

To elucidate the biological mechanism for methylation of diclofenac, diclofenac was spiked into the crude extract of the invertebrates and incubated for 24 h. Briefly, *G. pulex* (n=4) and *H. azteca* (n=30) were collected in a pre-weighed 2 mL microcentrifuge tube and flash-frozen in liquid nitrogen. After addition of 1 mL phosphate buffer (0.05 M, pH=7.5), the extraction and homogenization was carried out with an ultrasonic homogenizer Labsonic M (Sartorius Stedim Biotech, Switzerland) in four cycles of 30 s with an amplitude of 100% and 15−30 s break in between cycles (whole process performed under ice-cooling). Afterward, the homogenates were centrifuged (4 °C, 10'500 g, and 10 min). Supernatants were collected and used as crude extracts for incubation. For *in vitro* incubation, 250 µL of supernatant extracts were combined and mixed with 50 µL of 300 µg L$^{-1}$ (≈1µM) diclofenac in phosphate buffer and 25 µL of 10 mM S-adenosylmethionine (SAM) as co-factor in phosphate buffer, and incubated for 24 h at 16 °C (*G. pulex*) and 23 °C (*G. pulex* and *H. azteca*). After 2 h and 24 h, 125 µL aliquots of the incubation mixture were sampled and quenched by adding 175 µL of acetonitrile. These samples were centrifuged (4 °C, 10'500 g, 10 min) and the supernatants were collected in 2 mL glass vials and kept at −80 °C until LC-HRMS analysis.

The rainbow trout hepatocyte experiments were performed in triplicate in accordance with the draft guidelines for hepatocyte depletion assays (OECD 319A). An aliquot of 5 µL stock solution in ethanol was spiked into 1 mL of a hepatocyte suspension medium with a concentration of 2 x 10$^6$ cells mL$^{-1}$ in a 7 mL glass vial. The concentration of diclofenac at the start of the reaction was 636 µg L$^{-1}$ (≈ 2.14 µM). After 4 h incubation at 13 °C under gentle
shaking, the reactions were stopped by adding 4 mL of acetonitrile. Negative controls for abiotic reactions were run in parallel and under identical conditions using heat-inactivated hepatocytes.

**Acute Toxicity of Diclofenac and Diclofenac Methyl Ester**

Animals (n=10 per replicate, two replicates for each concentration) were separately exposed to increasing nominal concentrations of diclofenac (100 - 500 mg L\(^{-1}\) \(\cong\) 338 - 1688 µM) and diclofenac methyl ester (100 - 900 µg L\(^{-1}\) \(\cong\) 0.32 - 2.9 µM). The concentrations ranges of diclofenac and diclofenac methyl ester were selected based on preliminary range-finding tests. After 24 h of exposure, the number of deceased animals was counted. A glass rod was used to prod immobile organisms. An organism was defined as “dead” when no movement of its appendages was observed. All living organisms were quickly rinsed with ultrapure water, dried with tissue paper, transferred into the pre-weighed 2 mL centrifuge tubes, and weighed. Media and internal concentrations of diclofenac and diclofenac methyl ester were determined using the below-described online solid phase extraction (online SPE) and liquid chromatography high resolution tandem mass spectrometry (LC-HRMS/MS) method. The medium LC\(_{50}\) and the internal LC\(_{50}\) were determined by fitting a four-parameter log-logistic model (v. 5.02, GraphPad Software Inc., U.S.).

**Toxicity Classification**

We used a quantitative structure-activity relationship (QSAR) model for baseline toxicity and classification of specific modes of action of diclofenac and its metabolites. A large compilation of QSAR studies exist for fish (embryo) and some for *Daphnia magna*, but have not been established for *G. pulex*, and *H. azteca*. *G. pulex*, *H. azteca*, and *D. magna* are all freshwater crustaceans. Therefore, we adopted a QSAR model for *Daphnia magna*\(^{36}\) to predict
LC$_{50}$ of diclofenac and its metabolite diclofenac methyl ester in *G. pulex* and *H. azteca*. The equation for LC$_{50}$ (QSAR: predicted baseline toxicity) is described as follows:

$$\log\left(\frac{1}{\text{LC}_{50}}\right) = 0.77 \cdot \log D_{\text{lipw}}(\text{pH}) + 1.89$$

The liposome-water partitioning coefficient log $D_{\text{lipw}}$ of the ionic compound diclofenac was 2.6 (at pH=8) calculated by Baumer et al. based on COSMOmic. For the neutral chemical diclofenac methyl ester, log $D_{\text{ow}}$ (4.4) was used instead of log $D_{\text{lipw}}$(pH) (the liposome-water partitioning coefficient) in Equation (1). The toxic ratio (TR) analysis was used to classify the mode of action (MoA) (baseline toxicity or specific MoA) of diclofenac and its metabolite diclofenac methyl ester. TR was calculated based on the ratio of the LC$_{50}$ predicted with the baseline toxicity QSAR and the experimental LC$_{50}$ as follows (Eq. (2)):

$$\text{TR} = \frac{\text{LC}_{50}(\text{QSAR: predicted baseline toxicity})}{\text{LC}_{50}(\text{Experimental})}$$

For TR < 10, a chemical is considered as a baseline toxicant; for TR > 10, a chemical is considered specifically acting or reactive. 

**Sample Preparation**

In the tubes containing collected *G. pulex* and *H. azteca*, 100 µL of internal standard diclofenac-d$_4$ (100 µg L$^{-1}$), 500 µL of pure methanol and 300 mg of 1 mm zirconia/silica beads (BioSpec Products, Inc.) were added. A FastPrep bead beater (MP Biomedicals) was used for sample homogenization and extraction (15 s at 6 m s$^{-1}$, two cycles, cooling on ice in between). The homogenate was centrifuged (10'500 g x 6 min, 4 °C) and filtered through 0.45 µm regenerated cellulose filters (BGB Analytic AG). The filters were washed with 400 µL methanol and the filtrate and the wash solution were combined. The exposure media (500 µL) were sampled in 2 mL LC vials at 0 and 24 h, spiked with 100 µL of methanol containing diclofenac-
d$_4$ (100 μg L$^{-1}$), and 500 μL pure methanol, and were mixed evenly. We also examined whether the methylated metabolite of diclofenac had formed through chemical reactions in the presence of methanol during the preparation of sample extracts. In this case, the sample preparation steps for the non-exposed and exposed samples were similar to those described above, but using pure acetonitrile instead of methanol.

Sample preparation of fish hepatocyte assays was conducted in a similar way to that described in the OECD TG 319A.$^{35}$ Briefly, after the addition of acetonitrile solution and internal standard (10 ng diclofenac-d$_4$), the sampled cell suspension was vortex mixed for 10 minutes at 10'500 g. Subsequently, the cellular debris was pelleted by centrifugation (10 min at 10'500 g, 4°C). The supernatant sample was transferred into 4 mL glass vials. All samples were stored at -20 °C until chemical analysis.

Urine samples (2 mL) were centrifuged (10'500 g × 10 min, 4 °C) and the supernatants were analyzed using the below-described online SPE LC-HRMS/MS method on the same day.

**Chemical Analysis by LC-HRMS/MS and GC-HRMS/MS**

Details of all analytical approaches are provided in our previous study.$^{39}$ Briefly, all samples were primarily cleaned up and enriched with an automated online-SPE method, followed by the LC-HRMS/MS analysis using a Q Exactive or Q Exactive Plus mass spectrometer, fitted with an electrospray ionization interface, as the detector (Thermo Fisher Scientific Inc.). Full scan acquisition with a resolution of 70'000 (full width half maximum (FWHM) at 200 m/z) was conducted in polarity switching mode, followed by data-dependent MS/MS scans (five MS/MS scans in positive mode and two MS/MS scans in negative mode) with a resolution of 17'500 (FWHM at 200 m/z) and an isolation window of 1 Da. Water with 0.1% (vol.) formic acid and methanol with 0.1% (vol.) formic acid were used as mobile phases A
and B, respectively. Chromatographic separation was achieved on an XBridge C\textsubscript{18} column (3.5 µm, 2.1 x 50 mm, Waters) at 30 °C. The flow rate was 300 µL min\textsuperscript{-1} and the injection extracted volume was 200 µL (pre-enriched by online SPE). Directly before sample analysis, 200 µL extract was added to 20 mL headspace amber glass vials and filled up with 20 mL ultrapure water. The detailed parameters of LC-HRMS/MS are given in Tables S3 and S4. Quantification of parent compounds and biotransformation products with the available reference standard (e.g., diclofenac methyl ester and diclofenac taurine) was performed with the respective standard calibration method using the software TraceFinder v4.1 (Thermo Scientific). To test if diclofenac methyl ester could be formed during chemical analysis, diclofenac stock solutions were prepared in methanol, ethanol or acetonitrile and then analyzed by LC-HRMS/MS. Additionally, acetonitrile with 0.1% (vol.) formic acid was used instead of methanol with 0.1% (vol.) formic acid as mobile phase B together with mobile phase A (water with 0.1% (vol.) formic acid) to verify whether methylation of diclofenac would occur under LC-MS/MS conditions.

Triclosan methyl ether was analyzed by gas chromatography high resolution tandem mass spectrometry (GC-HRMS/MS) with positive mode electron ionization (Q Exactive, Thermo Fisher Scientific Inc.). For separation, we used an RTX-5MS column (15 m x 0.25 mm, 0.25 µm film thickness) equipped with a guard column (5 m x 0.25 mm). The column oven program started at 60 °C, was held for 1 min, increased at 10 °C/min to 300 °C, and was then held for 3 min. The transfer line temperature was 280 °C. Splitless injection of 1 µL was used at an injector temperature of 260 °C. Data analysis of triclosan methyl ether was performed by external standard calibration using the software Xcalibur Quan Browser (Thermo Scientific).

**Identification of Metabolites and Structure Elucidation**
The acquired HRMS/MS raw data were analyzed by Compound Discoverer software 2.1 (CD2.1) (Thermo Scientific, for criteria and parameter settings, see Table S5) with a suspect and non-target screening approach. Treatment and different control groups (i.e. chemical control, organism control, and sorption control) were compared by CD2.1 to generate the potential candidate list. The candidates were identified based on their unique presence in the treatment and/or 5-fold increase in the treatment compared to the control, peak intensity >10^5, and ≥3 scans in the extracted ion chromatograms. For the screening of possible metabolites, the generated candidate list was compared to the mass list of predicted metabolites, which was based on: (i) in silico manual prediction of metabolites considering the most common enzymatic biotransformation reactions, and (ii) already identified metabolites reported in any organism in the scientific literature. For non-target screening, the generated candidate list from CD2.1 was filtered with (i) a peak area threshold of 0.1% of the parent compound and (ii) an integrated intensity ratio between treatment and control samples of 5.

Structure elucidation was based on the: exact mass, isotopic pattern (Cl pattern), MS/MS spectral information, MS/MS information from available literature, in silico fragmentation tool (Mass Frontier v 7.0, HighChem), as well as reference standards. Finally, confidence levels of the metabolite identification were proposed according to Schymanski et al.40

Results and Discussion

Biotransformation of Diclofenac Leads to Various Metabolites in Different Species

Metabolite screening experiments in the presence of H. azteca and G. pulex were carried out with exposure to diclofenac for 24 h. Suspect and non-target screening strategies were applied to comprehensively identify metabolites in the test species using the data acquired with LC-HRMS/MS. The isotopic pattern of chlorine (Cl) was used to support the identification of Cl-
containing diclofenac metabolites. To determine the broader impact of diclofenac biotransformation, we investigated the biotransformation of diclofenac in other biological systems, including fish hepatocytes and humans. In all tested species, the transformation of diclofenac was detected (Fig. 1). In total, 17 diclofenac metabolites were detected across the tested biological systems, with nine detected in *H. azteca* and *G. pulex* and eight in fish hepatocytes and human urine (Fig. 1, Fig. S4). The postulated biotransformation reactions included methylation, hydroxylation, dehydration as well as conjugation with taurine, glutathione, glucose-sulfate and glucuronic acid (Fig. 1, Table S8). A biotransformation pathway based on the tentative chemical structures and biological reaction rationale is shown in Fig. 1. Among these metabolites, we unambiguously confirmed the structures of diclofenac methyl ester (DCF-M310.03) and diclofenac taurine (DCF-M403), using authentic reference standards (for details of the synthesis and NMR-based identification of diclofenac taurine, see SI. E and Fig. S1-3.). After 24 h exposure at media concentration of 0.2 mg L\(^{-1}\) diclofenac, the internal concentrations of diclofenac, biotransformed product DCF-M403 and DCF-M310.03 in exposed *H. azteca* were 120-158 ng g\(^{-1}\)\_ww (wet weight), 1761-1996 ng g\(^{-1}\)\_ww, and 0.7-116.5 ng g\(^{-1}\)\_ww, respectively, using different extraction solvents. These results suggest that the ratios of biotransformation products to parent compound were 12-17 for DCF-M403 and 0.01-0.7 for DCF-M310.03. Detailed quantification and discussions are given in SI.F, Fig. S4, and Table S7.
Figure 1. Proposed biotransformation pathways of diclofenac based on the organism-specific detection in *H. azteca* (H), *G. pulex* (G), and rainbow trout (*Oncorhynchus mykiss*) hepatocytes (F) and humans (U). More detailed information on the individual metabolites can be found in SI.J. and Table S8. Red arrows indicate phase I reactions and blue arrows indicate phase II reactions. Please note: all the metabolites are displayed in the neutral form. The number in the abbreviation of metabolites’ name stands for the molecular mass of the detected ion. Please note that identification confidence levels according to Schymanski et al. 40 are shown in Table S8.

Taurine conjugation of diclofenac (Fig. 1, entries DCF-M403) has previously been proposed as a minor reaction pathway in both mice41 and dogs.42 Here, for the first time, we have shown this to be a major pathway in the transformation of diclofenac in small aquatic invertebrates (Fig. 1 and S4). Similarly, taurine conjugation of azoxystrobin was identified for *H. azteca* in our previous study.39 In general, taurine conjugates of any compound are formed from compounds carrying a carboxylic acid group and have been identified in the large crustacean,43,44 fish,45,46 and humans.47,48 Hydroxylation and conjugation of diclofenac with glutathione, glucuronic acid, and sulfate (Fig. 1, entries DCF-M312, DCF-M371, DCF-M470, and DCF-M486) has also reported in other species, such as Mediterranean mussels (*Mytilus galloprovincialis*) and the rainbow trout (*Oncorhynchus mykiss*).18,49–52 Species specificity for the metabolic reactions was observed, e.g. glucuronic acid conjugation (Fig. 1, entries DCF-M470 and M486) was the major transformation product of diclofenac detected in humans 53 and fish hepatocytes, but was not observed in the tested invertebrates (Fig. 1, entries DCF-M470 and
M486), nor has it previously been detected in plants.\textsuperscript{54} Instead, glucose or amino acid (e.g., glutathione or glutamic acid) conjugations of diclofenac were predominant reactions in invertebrates (\textbf{Fig. 1}, entries DCF-M538), mussels \textsuperscript{52} or plants.\textsuperscript{54}

Among all metabolites, DCF-M310.03 via methylation of diclofenac emerged as an unexpected metabolite. Therefore, we have tried to rule out the possibility that DCF-M310.03 had formed as an artifact of our sample preparation or analysis procedures. To do so, several control samples were prepared to assess the formation of DCF-M310.03 through unexpected chemical reactions or as procedural artifacts (i.e. a false-positive result). In the absence of diclofenac (chemical control), neither diclofenac nor any of its metabolites were detected, suggesting that there was no background contamination. When applying diclofenac without organisms or in pure media, no obvious degradation of diclofenac nor formation of its metabolites was observed after 24 h, suggesting that there was no detectable abiotic transformation of diclofenac in the test system. We also examined whether DCF-M310.03 might have formed by chemical reactions in the presence of methanol during the preparation of stock solutions, sample extraction or LC separations. The results showed that no detectable amount of DCF-M310.03 was formed during sample extraction, nor in LC mobile phase containing methanol and 0.1\% formic acid or acetonitrile and 0.1\% formic acid, suggesting that methylation did not occur during sample preparation and LC-MS instrumental analysis. No DCF-M310.03 was detected in the ethanol stock solution of diclofenac sodium salt, nor in the methanol stock solution of diclofenac sodium salt. Only minor amounts of DCF-M310.03 (< 0.17\% with respect to diclofenac) were detected in the methanol stock solution of the free acid of diclofenac, formed either by methylation in the stock solution or more probably already present as an impurity in the diclofenac free acid standard. In this study, we used diclofenac sodium salt for preparing the
diclofenac stock solution. In conclusion, methylation due to the use of methanol as a solvent was negligible under the current experimental conditions.

Methylation of diclofenac, which had been tentatively proposed for rainbow trout (*Oncorhynchus mykiss*), has been unambiguously identified and quantified for the first time in the current study in the metabolic pathway of the selected invertebrates. It is worth noting that methylation of diclofenac emerged as an unexpected biotransformation pathway in *G. pulex, H. azteca*, fish hepatocytes, and human urine. DCF-M310.03 was detected in fish hepatocytes after 4 h exposure and in human urine after oral administration of diclofenac (1-8 h, formation kinetics shown in Fig. S5). In other studies, methylated metabolites have been previously identified in microorganisms such as methylation of tetrabromobisphenol-A (TBBPA) and of bisphenol A (BPA) in bacteria as well as of bezafibrate in algae. To determine the environmental relevance, we performed a retrospective analysis of digitally stored HRMS data to investigate DCF-M310.03 in muscle samples of 10 fish and 14 gammarid samples (diclofenac concentration: 1-5 ng g\(^{-1}\)ww) collected in wastewater-impacted streams. The retrospective analysis revealed that DCF-M310.03 was not present in the collection of field samples of fish and gammarids. However, based on the ratio of DCF and DCF-M310.03 in our lab experiments, as well as the limit of quantitation (LOQ) of DCF-M310.03 (low ng g\(^{-1}\)), we estimated the concentrations of DCF-M310.03 in field samples to have been below the LOQ.

We further screened five more widely used pharmaceuticals and pesticides (triclosan, atorvastatin, acemetacin, naproxen, and rosuvastatin) to test whether a methylation reaction was detectable for these compounds in invertebrates. We found that the methylation of triclosan occurred in *G. pulex and H. azteca*, but was not observed for atorvastatin, acemetacin, naproxen or rosuvastatin. The structural differences may contribute to the different methylation among
these chemicals. The formation of triclosan methyl ether was confirmed using an authentic reference standard (see SI. J). The methylation takes place at the hydroxyl group of triclosan leading to the methyl ether.

Methylated products may also undergo enzyme-catalyzed demethylation, which was confirmed by exposing *H. azteca* and *G. pulex* to only DCF-M310.03 for 24 h, as diclofenac was detected in both species. Demethylation was also observed for triclosan methyl ether in both invertebrates (SI. J). Demethylation of DCF-M310.03 is most probably catalyzed by ester hydrolases, while demethylation of triclosan methyl ether is catalyzed by cytochrome P450.56

Our observation is in line with previous studies describing the conversion of pollutant conjugates into their parental form (e.g. sulfamethoxazole, estrogens, trenbolone, triclosan, and carbamazepine) in the environment.25,26,57–59

**Formation of Diclofenac Methyl Ester by Enzymes in the Crude Extract**

We hypothesized that the DCF-M310.03 was formed from enzymatic reactions via methyltransferases in the biological systems. Two S-adenosylmethionine dependent O-methyltransferases are known, namely the caffeoyl-CoA O-methyltransferases, which catalyze phenolic groups, and the carboxylic acid O-methyltransferases, which catalyze carboxyl groups.60,61 Therefore, *in vitro* crude extracts from *G. pulex* and *H. azteca* were incubated with the co-factor S-adenosylmethionine and diclofenac for up to 24 h. In the control groups of the *in vitro* incubation experiment, no DCF-M310.03 was found. Methylation of diclofenac was detected in the *in vitro* experiments of enzymes extracted from adult *H. azteca*. This was not the case for either juvenile *H. azteca* nor adult *G. pulex*, *in vitro*. A possible explanation for this may be that the activity of the responsible enzymes might be lost or inhibited in the crude extract of juvenile *H. azteca* and *G. pulex*. It might also be that the activity of the responsible enzyme(s)
varies depending on the species and age. Our results from the *in vitro* enzymatic reactions indicate that methylation of diclofenac probably is catalyzed by the carboxylic acid O-methyltransferases in the tested biological systems. However, transformation by other unknown enzymes or bacteria in the crude extract cannot be fully excluded. Similarly, O-methyltransferases have been identified in plants, bacteria, yeast, and humans making this conclusion plausible.

**Significantly Higher Bioconcentration of the Metabolite Diclofenac Methyl Ester versus Diclofenac**

The formation of diclofenac methyl ester (DCF-M310.03) leads to significantly altered physicochemical properties. A physicochemical property that is of importance to toxicity and bioaccumulation, is changed by the methylation of the carboxylic group. The partitioning coefficient of diclofenac between octanol and water (log $D_{ow}$) is 0.9 (anionic at medium pH 7.9), while log $D_{ow}$ increases to 4.4 for DCF-M310.03 (neutral compound). Accordingly, bioconcentration potential and biological activity of DCF-M310.03 could be elevated compared to diclofenac and other known metabolites. Bioconcentration factors (BCFs) were calculated based on (1) *in silico* simulations using EPI 3.0 and (2) the ratio of the internal concentration of the chemical in the organisms to the concentration of the chemical in the exposure medium, at steady-state. The predicted BCFs of diclofenac and DCF-M310.03 (EPI 3.0 simulation) were 1.3 L kg$^{-1}$ and 351 L kg$^{-1}$, respectively, for lower trophic level fish (*Fig. 2A*), indicating a higher bioconcentration potential of DCF-M310.03 than diclofenac. The predicted BCFs of diclofenac and DCF-M310.03 were similar to the BCFs found in the experiment. For example, the experimentally determined BCFs of diclofenac were 0.5 and 3.2 L kg$^{-1}_{ww}$ in *H. azteca* and *G. pulex*, respectively, whereas BCFs of DCF-M310.03 was 164.5 L kg$^{-1}_{ww}$ and 104.7 L kg$^{-1}_{ww}$.
(Fig. 2B), respectively, which corresponds to a 25 to 110-fold increase. Thus, the higher BCFs of DCF-M310.03 compared to those of diclofenac in both organisms can actually be explained by the higher hydrophobicity of DCF-M310.03.

**Figure 2.** Comparison of the bioconcentration potential of diclofenac and diclofenac methyl ester (DCF-M310.03). Bioconcentration factor of diclofenac and DCF-M310.03 determined by (A) *in silico* prediction using EPI suite and (B) experimentally in *H. azteca* and *G. pulex* under static conditions after 24h.

**Comparison of the Toxicity between Diclofenac and its Major Metabolites**

The toxicity of two major metabolites (i.e., DCF-M310.03 and DCF-M403) was compared to the parent compound in two invertebrate species. The acute toxicity of diclofenac and DCF-M310.03 was assessed by deriving the 24-h media LC$_{50}$ values for *H. azteca* and *G. pulex* based on mortality. The LC$_{50}$ of diclofenac in media was 216 mg L$^{-1}$ and 175 mg L$^{-1}$ for *H. azteca* and *G. pulex*, respectively, indicating relatively low toxicity compared to environmental concentrations (Fig. 3A). However, the strongly reduced media LC$_{50}$ of 0.53 mg L$^{-1}$ obtained for DCF-M310.03 with *H. azteca* represents a 430-fold increase in acute toxicity compared to diclofenac (Fig. 3A). The LC$_{50}$ of DCF-M310.03 > 1 mg L$^{-1}$ in media was obtained for *G. pulex* but could not be exactly determined due to the limited water solubility of DCF-M310.03 (< 1 mg
Our results are consistent with previous observations that the methylated metabolites of BPA are more toxic than the parent compound, leading to increased toxicity to the developing zebrafish (Danio rerio) embryo.\(^{29}\)

**Figure 3.** Lethal toxicity of diclofenac and DCF-M310.03 towards H. azteca. (A) Medium concentration–response (mortality) curves of lethal toxicity of diclofenac and DCF-M310.03; (B) Internal concentration of diclofenac and DCF-M310.03 in H. azteca at the corresponding media LC\(_{50}\). LC\(_{50}\) Diclofenac: media concentration of diclofenac at the LC\(_{50}\); LC\(_{50}\) DCF-M310.03: media concentration of DCF-M310.03 at the LC\(_{50}\). Student t-test, unpaired.

Internal concentrations of the chemicals reflect the organism’s actual exposure that links to the observed toxicological effects. We therefore determined the internal concentrations (body residue) of diclofenac and DCF-M310.03 in H. azteca using LC-HRMS/MS (Fig. S6). For H. azteca at media LC\(_{50}\) concentrations of diclofenac (216 mg L\(^{-1}\)) or DCF-M310.03 (0.5 mg L\(^{-1}\)) as shown in Fig. 3A, very similar internal concentrations of DCF-M310.03 of 157 ± 43 mg kg\(^{-1}\) \(_{\text{ww}}\) and 83 ± 23 mg kg\(^{-1}\) \(_{\text{ww}}\) were determined, respectively. In contrast, the internal levels of diclofenac significantly differed (\(p < 0.05\)) by one order of magnitude (Fig. 3B). This observation indicates that DCF-M310.03 likely contributes more to the observed toxicity while both diclofenac and DCF-M310.03, as a mixture, might be of relevance.
The acute toxicity of another major metabolite DCF-M403 was also compared to the data of the parent compound diclofenac. Due to the limited availability of synthesized DCF-M403 (SI, E and Fig. S1-3.), we were only able to determine the toxicity difference at a concentration of 220 mg L\(^{-1}\) (similar to media LC\(_{50}\) of diclofenac). In two separate batches, \(H. \text{ azteca}\) was exposed to 220 mg L\(^{-1}\) of diclofenac or DCF-M403 for 24 h each. About 50% of the organisms died at 220 mg L\(^{-1}\) of diclofenac after 24 h, while no death was observed at 220 mg L\(^{-1}\) of DCF-M403. These results suggest that DCF-M403 is less toxic than its parent compound diclofenac towards \(H. \text{ azteca}\), which may be linked to the slightly lower hydrophobicity of DCF-M403 (log \(D_{\text{ow}}\) (pH 7.9), 0.3) as compared to diclofenac (log \(D_{\text{ow}}\) (pH 7.9), 0.9).

**Mode of Action of Diclofenac and its Metabolite Diclofenac Methyl Ester**

The mode of action (MoA) for acute toxicity of diclofenac and DCF-M310.03 towards \(H. \text{ azteca}\) at environmentally-relevant pH 7.9, were evaluated. Toxic ratios (TR) of 3.3 and 0.2 were determined for diclofenac and DCF-M310.03, respectively, which were within the baseline toxicity range (0.1 \(<\) TR \(<\) 10), meaning that both compounds are classifiable as baseline toxicants towards \(H. \text{ azteca}\). In contrast, diclofenac was recently classified as a specific toxic chemical with a high TR (TR = 35) towards zebrafish, explained with the specific cyclooxygenase inhibition (COX) assay.\(^{38}\) This discrepancy may be attributed to differences in the diclofenac-COX interactions between invertebrates and vertebrates.

**Environmental Implications**

We have shown that diclofenac unexpectedly produces a more bioaccumulative and toxic metabolite in invertebrates, fish and humans that could contribute to enhanced toxicity not previously reported. In addition to diclofenac, we also observed that the methylation of triclosan
occurred in two keystone invertebrates, while methylation was not observed for atorvastatin, acemetacin, naproxen, and rosuvastatin in the same species. These findings indicate that methylation is relevant only for certain compounds. Methylation leads to more hydrophobic metabolites for some polar emerging contaminants, which in turn leads to enhanced bioaccumulation and associated toxicity across different non-target species. Accordingly, potentially methylated metabolites should be screened to allow for better risk assessment of polar contaminants in the future. A full consideration of both methylation and demethylation conversion is needed to better understand the dynamics of the methylated products and their precursors in aquatic organisms.

Environmental concentrations of most contaminants are much lower than the concentrations used in this study, which were necessary to identify the metabolites. In future studies, methylated metabolites should be screened for field samples, however, extremely sensitive analytical methods are necessarily required.

**Supplementary Materials:** Additional details (Materials and Methods. S1-S4; Figs. S1 to S11; Tables S1 to S8) are available free of charge via the Internet at [http://pubs.acs.org/](http://pubs.acs.org/).

**Competing Interests:** Authors declare no competing interests.

**Acknowledgments**

This research was financially supported by the Swiss National Science Foundation (grant number 205320165935) and the European Chemical Industry Council's Long-Range Research Initiative program (Cefic-LRi) (ECO 40 project). The NMR hardware was partially granted by the Swiss National Science Foundation (SNSF, grant no. 206021_150638/1). We thank Martin Jones, Andrea Rösch, and Marion Junghans (all Eawag) for helpful discussion and proofreading.
of the manuscript. Furthermore, we appreciate Markus Zennegg (Empa) and Jakov Bolotin (Eawag) for support with the GC-HRMS/MS analysis as well as Marco Fleischmann and Cornel Niederhauser for assistance with the DCF-M403 standard synthesis. We thank volunteers for their participation in the trial and Michael Patrick (Eawag) for help in the sample preparation. We also thank ChemAxon (Budapest, Hungary) for an academic license of Marvin/Calculator Plugins. Last but not least, we thank the four anonymous reviewers for taking their time to carefully review our manuscript and provide valuable comments that contributed to the improvement of this manuscript.

References


Jelic, A.; Gros, M.; Ginebreda, A.; Cespedes-Sánchez, R.; Ventura, F.; Petrovic, M.; Barcelo, D.


ACS Paragon Plus Environment


(25) Qu, S.; Kolodziej, E. P.; Long, S. A.; Gloer, J. B.; Patterson, E. V.; Baltrusaitis, J.; Jones, G. D.; Benchetler,


(33) Vizioli, E. D.; Chin, C. M.; Menegon, R. F.; Blau, L.; Santos, J. L.; Longo, M. D. Compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these, 2013.

(34) Bischof, I.; Köster, J.; Segner, H.; Schlechtriem, C. Hepatocytes as in vitro test system to investigate metabolite patterns of pesticides in farmed rainbow trout and common carp: Comparison between in vivo

(35) OECD. *OECD test guideline No.319A*; 2018.


(43) James, M. O. Disposition and taurine conjugation of 2,4-dichlorophenoxyacetic acid, 2,4,5-trichlorophenoxyacetic acid, bis(4-chlorophenyl)acetic acid, and phenylacetic acid in the spiny lobster, *Panulirus argus*. *Drug Metab. Dispos.* 1982, 10 (5), 516–522.


(46) James, M. O.; Bend, J. R. Taurine conjugation of 2,4-dichlorophenoxyacetic acid and phenylacetic acid in two marine species. *Xenobiotica* 1976, 6 (7), 393–398.


(54) Fu, Q.; Ye, Q.; Zhang, J.; Richards, J.; Borchartd, D.; Gan, J. Diclofenac in Arabidopsis cells: Rapid


(56) James, M. O.; Marth, C. J.; Rowland-Faux, L. Slow O-demethylation of methyl triclosan to triclosan, which is rapidly glucuronidated and sulfonated in channel catfish liver and intestine. *Aquat. Toxicol.* **2012**, *124–125*, 72–82.


30